Eden Members’ Self Reported Survey Results
- Filter Applied: Users Who Reported Weight Loss
- Initial BMI Range: 36 – 63.5
- Days Since Treatment Started: 170 – 343
- Total Reported Weight Loss: -6,745 lbs
- Average Reported Weight Loss: -26.8 lbs
- % Users Who Reported Weight Loss: 98%
Self-Reported User Data
Our latest internal snapshot highlights outcomes shared by a group of Eden members who were using compounded GLP-1 medications, such as compounded semaglutide, and chose to report progress as part of their ongoing wellness journey. To be included in this internal survey, users had to meet the following criteria:
- Reported weight loss during treatment (98% of users in this group reported a reduction)
- Had an initial BMI between 36 and 63.5
- Were engaged in treatment for 170 to 343 days (approx. 6 to 11 months)
Results: Members in this self-reported group shared an average body weight reduction of 11.6% during their reporting window.
Key Findings
- Total Users Analyzed: 111
- Average Weight Loss: 29.3 lbs
- Average % Body Weight Loss: 11.6%
- Treatment Duration: 170–343 days
- User Selection Criteria: Individuals who submitted weight loss data
- Average Initial BMI: 36–63.5
Note: These results reflect self-reported data from users who experienced weight loss and do not represent typical outcomes.Individual results vary. This is not a clinical study and has not been independently verified.
Why It’s Meaningful to Users
While not a clinical trial, this internal reporting helps us understand how some Eden members are tracking changes over time. Many participants exceeded 10% weight reduction in their self-reported data — a figure that some medical literature has associated with meaningful changes in overall wellness.*
*Generalized statements based on public research. No health or treatment outcomes are guaranteed. Medications may carry risks and side effects. Please consult a licensed medical professional for personalized care.
Eden Progress Tracking Methodology
To support transparency and help users stay accountable, Eden tracks self-reported progress submitted during refill check-ins. This approach allows us to better understand how users engage with their treatment plans and monitor outcomes over time.
Data Collection Process
- User Check-In via Refills
- Each time a patient requests a refill, it’s treated as a medical check-in.
- Users are prompted to enter their current weight during this process.
- This data is linked to a unique User ID and timestamped.
- Data from EMR Partner
- Eden’s EMR and fulfillment partners send updated user data every two months, which includes:
- User ID
- Refill timestamp
- Reported weight
- Medication identifier (e.g., Semaglutide, Tirzepatide)
- Eden’s EMR and fulfillment partners send updated user data every two months, which includes:
Important Disclosures
- Eden does not manufacture medications or provide medical care.
- All prescriptions are evaluated and written by licensed, independent physicians.
- Medications are filled and shipped by licensed compounding pharmacies.
- Eden facilitates access to care and provides progress tracking tools — we do not guarantee individual results.
Personalization with Eden Survey Results
This survey asked 17 questions and received a total of 4,649 unique responses.
Key Findings
Would you recommend treatment to a family member or friend?
- Yes: 4,262 respondents (91.59%)
- No: 388 respondents (8.34%)
Since starting your plan with Eden, have you seen improvements in any of the following?
- Inflammation: 1,142 respondents (24.56%)
- General weight management: 3,367 respondents (72.42%)
- Triglyceride levels: 433 respondents (9.31%)
- Blood sugar levels: 775 respondents (16.67%)
- Sleep quality: 968 respondents (20.82%)
- Heart health: 405 respondents (8.71%)
- Quality of Life: 2,047 respondents (44.03%)
- Mood: 1,801 respondents (38.73%)
- None of the above: 574 respondents (12.35%)
Why It’s Meaningful to Users
While this is not a clinical trial, these self-reported responses provide a valuable glimpse into how many Eden members are experiencing meaningful change. A significant majority (91.6%) said they would recommend the treatment to others, and over 70% reported improved weight management. Many also saw positive impacts across multiple areas of health, from inflammation and sleep quality to mood and overall quality of life. Nearly 91% agreed that treatment positively influenced their body image and self-confidence.
Note: These findings reflect internal, self-reported data and are not intended to represent clinical outcomes. Individual results vary. Medications may carry risks and side effects. Please consult a licensed medical provider for personalized medical advice.